CCL22 and hepatocellular carcinoma: For instance, Tregs, which abundantly express CCR4, CCR8 and CCR10, were directed to hepatocellular carcinoma (HCC) sites, where their corresponding ligands, CCL22 and CCL28, were present, affecting the treatment outcome by evading the immune system (27).